Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Biocad
- Target Recruit Count
- 158
- Registration Number
- NCT02753088
Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Biocad
- Target Recruit Count
- 399
- Registration Number
- NCT02744222
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of Nizhny Novgorod region " "Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod", Nizhny Novgorod, Russian Federation
Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Biocad
- Target Recruit Count
- 159
- Registration Number
- NCT02744196
Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- Biocad
- Target Recruit Count
- 45
- Registration Number
- NCT02731469
Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Biocad
- Target Recruit Count
- 163
- Registration Number
- NCT02727907
- Locations
- 🇷🇺
Scientific neurology center, RAS, Moscow, Russian Federation
Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Biocad
- Target Recruit Count
- 74
- Registration Number
- NCT02506881
- Locations
- 🇷🇺
City Mariin Hospital, St. Petersburg, Russian Federation
Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Biocad
- Target Recruit Count
- 196
- Registration Number
- NCT02506868
- Locations
- 🇷🇺
NEFROS Ltd, Medical Centre, Krasnodar, Russian Federation
🇷🇺N.I.Pirogov City Clinical Hospital #1, Moscow, Russian Federation
🇷🇺Alyans Biomedical - Ural'skaya gruppa, Izhevsk, Russian Federation
Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Biocad
- Registration Number
- NCT02450981
Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Biocad
- Target Recruit Count
- 94
- Registration Number
- NCT02395055
- Locations
- 🇷🇺
LLC BioEk, Saint-Petersburg, Russian Federation
First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Biocad
- Target Recruit Count
- 22
- Registration Number
- NCT02380287
© Copyright 2024. All Rights Reserved by MedPath